The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.

Of note, low expression of PTEN or INPP4B (below median H ‐score value) and mutations in the PIK3CA/AKT/mTOR pathway were associated with higher expression of p4EBP1 or pS6 with borderline significance (data not shown).

also in 7,017 other papers